Drugs / PRT12396
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07469891 | Apr 2026 → Apr 2028 expected | acquired polycythemia vera, myelofibrosis, primary myelofibrosis | Prelude Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-02-03 | Prelude Therapeutics | Regulatory Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor preludetx.com ↗
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT12396, a mutant-selective JAK2V617F inhibitor being developed for the treatment of patients with certain myeloproliferative neoplasms (MPNs). |
| 2025-12-06 | Prelude Therapeutics | Results Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs preludetx.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-03 | Prelude Therapeutics | Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor preludetx.com ↗ |
| 2025-12-06 | Prelude Therapeutics | Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs preludetx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRT12396 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07469891 ↗ |
| Route | Oral | “PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE.” NCT07469891 ↗ |